SCHEMBL27717174

SCHEMBL27717174

CC(C)(C)OC(=O)N1CCN(c2cncnn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 11/20 0.53
▸ CKS1B P61024 2/20 0.51
▸ SKP1 P63208 2/20 0.51
▸ SKP2 Q13309 2/20 0.51
▸ MAP4K4 O95819 1/20 0.49
▸ SMARCA2 P51531 1/20 0.46
▸ SMARCA4 P51532 1/20 0.46
▸ PBRM1 Q86U86 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HTT P42858 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ DDB1 Q16531 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2227063 0.80 GPR119 (0.56) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL4316079 0.80 CKS1B (0.55) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL12964697 0.80 GPR119 (0.79) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL38663361 0.79 CKS1B (0.49) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL18790713 0.79 CKS1B (0.49) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL29473497 0.78 TRPV1 (0.57) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL20140603 0.78 TRPV1 (0.57) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL23560770 0.78 CKS1B (0.57) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL15114941 0.78 CKS1B (0.48) GPR119CKS1BSKP1SKP2MAP4K4
SCHEMBL28101296 0.78 CKS1B (0.50) GPR119CKS1BSKP1SKP2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101146796-A 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer SCHERING CORP (US) 2008-03-19 — — CN disclosed
Send feedback